February 13th 2025
A study finds that esketamine during cesarean delivery may reduce postpartum depression risk, though further research is needed to confirm its safety and efficacy.
Satellite Symposia at the 2025 Oncology Nursing Society Congress
April 11-12, 2025
Register Now!
16th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™
May 3, 2025
View More
Addressing Healthcare Inequities: Tailoring Cancer Screening Plans to Address Inequities in Care
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine
View More
Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings
View More
Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine
View More
Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Navigating Low-Grade Serous Ovarian Cancer – Enhancing Diagnosis, Sequencing Therapy, and Contextualizing Novel Advances
View More
Burst CME™: Implementing Appropriate Recognition and Diagnosis of Low-Grade Serous Ovarian Cancer
View More
Burst CME™: Stratifying Therapy Sequencing for LGSOC and Evaluating the Unmet Needs of the Standard of Care
View More
Burst CME™: Understanding Novel Advances in LGSOC—A Focus on New Mechanisms of Action and Clinical Trials
View More
Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations
View More
Expert Illustrations and Commentaries™: Visualizing Glucocorticoid Receptor Modulation in Platinum-Resistant Ovarian Cancer—Looking at Novel Pathways With an Eye Toward the Future of Treatment
View More
Q: Is the treatment for Osteoporosis different for males than females? I am a 67 year old male. Recently by x-rays of my back, it was stated in the report that I have osteoporosis . In a phone conversation with my primary physician's assistant, he stated that I should be on hormones, but that he would have to run it by the primary physician. Since that time, and this was at thanksgiving, I have tried to make contact, by phone to the primary physician. I was told, by office personnel, that I should make an appointment to discuss the situation. My question is, why is it necessary to discuss treatment face to face? Can't he advise me by phone? What is necessary? My schedule is very irregular and also why the extra expense for an office visit just to say here is what you do and if a prescription is necessary, can't he call it in as has been done on other occasions. I would like to know also, isn't it rather uncommon for a male to have this condition? Could you tell me what is the usual treatment in this kind of situation?
Read More
What Is the Evidence that rFSH Is Better than uFSH?
February 7th 2007In infertile women undergoing therapy with assisted reproductive techniques, such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), the use of gonadotropins to achieve multifollicular development is now well established.
Read More
The routine transfer of cleavage stage embryos to the patient’s uterus on day 2 or 3 has two inherent drawbacks; firstly the embryo does not reside in the uterus at such time, and secondly, up to the 8-cell stage one is observing a cleaving oocyte, in that the majority of embryonic genes have not been activated.
Read More